|1.||Study Group: 2 articles (07/2001 - 03/2001)|
|2.||Diener, H C: 2 articles (07/2001 - 03/2001)|
|3.||Tfelt-Hansen, P: 1 article (07/2001)|
|4.||Ferrari, M D: 1 article (07/2001)|
|5.||Dahlöf, C: 1 article (07/2001)|
|6.||de Beukelaar, F: 1 article (07/2001)|
|7.||Olesen, J: 1 article (07/2001)|
|8.||Mathew, N: 1 article (07/2001)|
|9.||De Beukelaar, F: 1 article (03/2001)|
|10.||Schellens, R: 1 article (03/2001)|
|1.||Migraine Disorders (Migraine)
03/01/2001 - "Alniditan 2 mg, administered via the intranasal route, was effective in relieving migraine headaches in over two-thirds of the patients at 1 h."
03/01/2001 - "In this open phase-II clinical tolerability trial 17 neurologists enrolled a total of 112 patients and instructed them to administer a maximum of two doses of intranasal alniditan, a 5-HT1B/D receptor agonist, for the treatment of three consecutive migraine attacks of moderate to severe intensity. "
03/01/2001 - "Treatment of migraine attacks with intranasal alniditan: an open study."
11/01/1996 - "Both of these suggestions warrant further and larger trials of alniditan in acute migraine."
11/01/1996 - "In a multinational double-blind randomized parallel-groups dose-finding trial, alniditan was given subcutaneously in hospital to patients with migraine headache of moderate or severe intensity at doses of 0.8 mg (n = 44), 1.0 mg (n = 42), 1.2 mg (n = 46) and 1.4 mg (n = 39). "
11/01/1996 - "Time to onset of relief decreased with increasing alniditan dose, and there was a dose-dependent reduction in headache recurrence rate: 25% of patients receiving 1.4 mg had responded by 15 min and headache recurred within 24 h in only 16% of the patients who initially responded to alniditan 1.4 mg, significantly less than for placebo (p = 0.018). "
11/01/1996 - "At 2 h after injection, headache was absent or mild in 83% and 82% of patients receiving alniditan 1.2 and 1.4 mg respectively compared with 39% for placebo (p < or = 0.002). "
03/01/1999 - "To compare the pharmacokinetic profile of intranasal alniditan during and outside migraine attacks, and to investigate the relationship between initial rise of alniditan plasma concentration, and headache improvement. "
11/01/1996 - "Comparison with published findings suggests that alniditan 1.4 mg sc may have advantages over sumatriptan 6 mg sc in providing complete relief from acute migraine headache, and may be associated with fewer headache recurrences within 24 h. "
07/01/2001 - "The number of subjects who were pain free at 2 h (primary endpoint) was: 22 (14.1%) with placebo, 174 (56.3%) with alniditan 1.4 mg, 87 (61.7%) with alnditan 1.8 mg and 209 (65.9%) with sumatriptan 6 mg. Alniditan 1.4 mg was significantly better (P < 0.001) than placebo and sumatriptan was significantly better (P = 0.015) than alniditan 1.4 mg. The number of responders (reduction of headache severity from moderate or severe headache before treatment to mild or absent at 2 h), was 59 (37.8%) on placebo, 250 (80.9%) on alniditan 1.4 mg, 120 (85.1%) on alniditan 1.8 mg, and 276 (87.1%) on sumatriptan. "
12/01/1996 - "We further compared the properties of [3H]alniditan, as a new radioligand for 5-HT1D-type receptors, with those of [3H]5-HT in membrane preparations of calf substantia nigra, C6 glioma cells expressing h5-HT1D alpha, and L929 cells expressing h5-HT1D beta receptors. "
04/01/1998 - "2. Sodium butyrate treatment increased the expression level of human (h)5-HT1B receptors in HEK 293 cells and h5-HT1D receptors in C6 glioma cells approximately 3 fold, the binding affinities of [3H]-5-HT and [3H]-alniditan were unaffected. "
04/01/1998 - "We compared the agonistic properties of alniditan, sumatriptan and dihydroergotamine on the cloned human 5-HT1B receptor expressed at 200 fmol mg(-1) protein (Bmax) in non-induced L929sA cells, at 740 fmol mg(-1) protein in HEK 293 and at 2300 fmol mg(-1) protein in mIFNbeta-induced L929sA cells, and on the human cloned 5-HT1D receptor expressed in C6 glioma cells (Bmax 780 fmol mg(-1) protein). "
|4.||Photophobia (Light Sensitivity)
10/08/1999 - "Alniditan dose dependently attenuated the neurogenic inflammation and was more potent than sumatriptan. "
10/08/1999 - "The non-indole 5-HT receptor agonist, alniditan (R 91274), was tested and compared to sumatriptan in an in vivo model of neurogenic inflammation within the meninges of rats and in rat basilar artery in a Mulvany-Halpern chamber in vitro. "
|2.||Serotonin (5 Hydroxytryptamine)
|6.||Serotonin 5-HT1 Receptor Agonists
|7.||5-HT1D Serotonin Receptor
|8.||5-HT1B Serotonin Receptor